BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPUVIZ (aflibercept-yszy) by Samsung Bioepis. Approved for diabetic macular edema, neovascular age-related macular degeneration. First approved in 2024.
Drug data last refreshed 22h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on OPUVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.